Decreased libido + Dihydrocodeine
Dihydrocodeine is known to produce decreased libido, a physical effect. Decreased libido is a diminished interest in and desire for sexual activity, commonly caused by substances that suppress dopaminergic reward signaling, dampen emotional responsiveness, or induce sedation.
About Decreased libido
Decreased libido refers to a measurable reduction in sexual desire, the anticipation of sexual activity, and the tendency to perceive situations or stimuli as sexually relevant. Under its influence, an individual may find that sexual thoughts, fantasies, and urges are diminished or entirely absent, and that stimuli which would normally provoke arousal feel neutral or uninteresting. This can range from a subtle dampening of sexual interest to a complete absence of any sexual motivation.
The neuropharmacology of decreased libido involves several pathways depending on the substance class. Opioids are among the most potent libido suppressors, both through direct suppression of the hypothalamic-pituitary-gonadal axis (reducing testosterone and estrogen production) and by flooding dopaminergic reward circuits with such intense non-sexual pleasure that sexual motivation becomes relatively uncompelling.SSRIs and serotonergic compounds suppress libido through excess serotonergic activity, which has an inhibitory relationship with dopaminergic sexual motivation pathways.GABAergic depressants reduce libido through general CNS depression and emotional blunting.Antipsychotics suppress libido primarily through dopamine D2 receptor blockade and prolactin elevation.
This effect is often accompanied by other sexual dysfunction effects including temporary erectile dysfunction and orgasm suppression, creating a constellation of sexual impairment that many users find frustrating, particularly when using substances like MDMA that simultaneously increase emotional intimacy and desire for physical closeness while impairing the ability to act on those feelings. The disconnect between wanting emotional and physical connection but lacking sexual drive is a commonly discussed experience in harm reduction communities.
For individuals on chronic medications (particularly SSRIs, antipsychotics, and opioid maintenance therapy), decreased libido can become a persistent quality-of-life concern that significantly affects relationships and well-being. This is one of the most commonly cited reasons for medication non-compliance with antidepressants — a pattern that carries its own serious risks. Anyone experiencing medication-related libido issues should discuss them openly with their prescriber rather than abruptly discontinuing treatment.